Effects of the α(1a)-adrenoceptor antagonist RS-17053 on phenylpropanolamine-induced anorexia in rats

P. J. Wellman, L. R. McMahon, Thomas Green, A. Tole

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Activation of α1-Adrenergic receptors via systemic administration of dugs such as phenylpropanolamine (PPA) and cirazoline results in the suppression of feeding in rats. Whether PPA acts via activation of the three currently identified α1-Adrenoceptor subtypes is unknown. The intent of the present study was thus to examine the effects of systemic administration of the novel α(1a)-Adrenoceptor antagonist RS-17053 on PPA-induced anorexia. Adult male rats (n = 6 to 8 per group) were pretreated (IP) with either 0,0.1,0.5,2.5 or 10.0 mg/kg RS-17053 or with 2.0 mg/kg of the prototypical α1-Adrenoceptor antagonist prazosin. Five minutes later each rat was treated (Ip) with either 0.5, 10 or 1.5 mg/kg PPA. Food and water intakes were recorded for a 30 min period starting 10 min after the treatment injection. Rats pretreated with vehicle and then treated with PPA exhibited a dose-dependent suppression of feeding with a maximal effect evident at the 1.5 mg/kg dose of PPA. Pretreatment with RS-17053 (0.1-2.5 mg/kg) did not alter either baseline feeding or the anorexic action of PPA. These results suggest that PPA does not act via the {1a)-Adrenergic receptor subtype to suppress food intake.

Original languageEnglish (US)
Pages (from-to)281-284
Number of pages4
JournalPharmacology Biochemistry and Behavior
Volume57
Issue number1-2
DOIs
StatePublished - May 1997
Externally publishedYes

Fingerprint

Phenylpropanolamine
Anorexia
Adrenergic Receptors
Rats
Eating
Chemical activation
RS 17053
Prazosin
Drinking
Injections
Water

Keywords

  • α1-Adrenergic receptors
  • Anorexia
  • Phenylpropanolamine
  • Prazosin
  • RS-17053

ASJC Scopus subject areas

  • Biochemistry
  • Behavioral Neuroscience
  • Pharmacology

Cite this

Effects of the α(1a)-adrenoceptor antagonist RS-17053 on phenylpropanolamine-induced anorexia in rats. / Wellman, P. J.; McMahon, L. R.; Green, Thomas; Tole, A.

In: Pharmacology Biochemistry and Behavior, Vol. 57, No. 1-2, 05.1997, p. 281-284.

Research output: Contribution to journalArticle

@article{0220f8f4f1944aa78683591a65d08a0e,
title = "Effects of the α(1a)-adrenoceptor antagonist RS-17053 on phenylpropanolamine-induced anorexia in rats",
abstract = "Activation of α1-Adrenergic receptors via systemic administration of dugs such as phenylpropanolamine (PPA) and cirazoline results in the suppression of feeding in rats. Whether PPA acts via activation of the three currently identified α1-Adrenoceptor subtypes is unknown. The intent of the present study was thus to examine the effects of systemic administration of the novel α(1a)-Adrenoceptor antagonist RS-17053 on PPA-induced anorexia. Adult male rats (n = 6 to 8 per group) were pretreated (IP) with either 0,0.1,0.5,2.5 or 10.0 mg/kg RS-17053 or with 2.0 mg/kg of the prototypical α1-Adrenoceptor antagonist prazosin. Five minutes later each rat was treated (Ip) with either 0.5, 10 or 1.5 mg/kg PPA. Food and water intakes were recorded for a 30 min period starting 10 min after the treatment injection. Rats pretreated with vehicle and then treated with PPA exhibited a dose-dependent suppression of feeding with a maximal effect evident at the 1.5 mg/kg dose of PPA. Pretreatment with RS-17053 (0.1-2.5 mg/kg) did not alter either baseline feeding or the anorexic action of PPA. These results suggest that PPA does not act via the {1a)-Adrenergic receptor subtype to suppress food intake.",
keywords = "α1-Adrenergic receptors, Anorexia, Phenylpropanolamine, Prazosin, RS-17053",
author = "Wellman, {P. J.} and McMahon, {L. R.} and Thomas Green and A. Tole",
year = "1997",
month = "5",
doi = "10.1016/S0091-3057(96)00351-6",
language = "English (US)",
volume = "57",
pages = "281--284",
journal = "Pharmacology Biochemistry and Behavior",
issn = "0091-3057",
publisher = "Elsevier Inc.",
number = "1-2",

}

TY - JOUR

T1 - Effects of the α(1a)-adrenoceptor antagonist RS-17053 on phenylpropanolamine-induced anorexia in rats

AU - Wellman, P. J.

AU - McMahon, L. R.

AU - Green, Thomas

AU - Tole, A.

PY - 1997/5

Y1 - 1997/5

N2 - Activation of α1-Adrenergic receptors via systemic administration of dugs such as phenylpropanolamine (PPA) and cirazoline results in the suppression of feeding in rats. Whether PPA acts via activation of the three currently identified α1-Adrenoceptor subtypes is unknown. The intent of the present study was thus to examine the effects of systemic administration of the novel α(1a)-Adrenoceptor antagonist RS-17053 on PPA-induced anorexia. Adult male rats (n = 6 to 8 per group) were pretreated (IP) with either 0,0.1,0.5,2.5 or 10.0 mg/kg RS-17053 or with 2.0 mg/kg of the prototypical α1-Adrenoceptor antagonist prazosin. Five minutes later each rat was treated (Ip) with either 0.5, 10 or 1.5 mg/kg PPA. Food and water intakes were recorded for a 30 min period starting 10 min after the treatment injection. Rats pretreated with vehicle and then treated with PPA exhibited a dose-dependent suppression of feeding with a maximal effect evident at the 1.5 mg/kg dose of PPA. Pretreatment with RS-17053 (0.1-2.5 mg/kg) did not alter either baseline feeding or the anorexic action of PPA. These results suggest that PPA does not act via the {1a)-Adrenergic receptor subtype to suppress food intake.

AB - Activation of α1-Adrenergic receptors via systemic administration of dugs such as phenylpropanolamine (PPA) and cirazoline results in the suppression of feeding in rats. Whether PPA acts via activation of the three currently identified α1-Adrenoceptor subtypes is unknown. The intent of the present study was thus to examine the effects of systemic administration of the novel α(1a)-Adrenoceptor antagonist RS-17053 on PPA-induced anorexia. Adult male rats (n = 6 to 8 per group) were pretreated (IP) with either 0,0.1,0.5,2.5 or 10.0 mg/kg RS-17053 or with 2.0 mg/kg of the prototypical α1-Adrenoceptor antagonist prazosin. Five minutes later each rat was treated (Ip) with either 0.5, 10 or 1.5 mg/kg PPA. Food and water intakes were recorded for a 30 min period starting 10 min after the treatment injection. Rats pretreated with vehicle and then treated with PPA exhibited a dose-dependent suppression of feeding with a maximal effect evident at the 1.5 mg/kg dose of PPA. Pretreatment with RS-17053 (0.1-2.5 mg/kg) did not alter either baseline feeding or the anorexic action of PPA. These results suggest that PPA does not act via the {1a)-Adrenergic receptor subtype to suppress food intake.

KW - α1-Adrenergic receptors

KW - Anorexia

KW - Phenylpropanolamine

KW - Prazosin

KW - RS-17053

UR - http://www.scopus.com/inward/record.url?scp=0031004198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031004198&partnerID=8YFLogxK

U2 - 10.1016/S0091-3057(96)00351-6

DO - 10.1016/S0091-3057(96)00351-6

M3 - Article

VL - 57

SP - 281

EP - 284

JO - Pharmacology Biochemistry and Behavior

JF - Pharmacology Biochemistry and Behavior

SN - 0091-3057

IS - 1-2

ER -